Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Capital Markets

Colgate Palmolive Co / Equity Capital Markets

<ul><li>Colgate-Palmolive delivered a decent result, surpassing revenue expectations of Wall Street as a result of continued business momentum.</li><li>The company witnessed a 5% organic growth which was driven by a combination of price increases as well as volume growth.</li><li>However, despite the price increase, the management has failed to prevent a margin contraction at the gross margin level.</li></ul>

Colgate-Palmolive delivered a decent result, surpassing revenue expectations of Wall Street as a result of continued business momentum.The company witnessed a 5% organic growth which was driven by a combination of price increases as well as volume growth.However, despite the price increase, the management has failed to prevent a margin contraction at the gross margin level.

Colgate-Palmolive Company - Investment Thesis

Value Investing

Vladimir Dimitrov, CFA

Equity Bottom-Up

<ul>
<li>Over the past few years Procter &amp; Gamble has been outperforming its peers in the Home &amp; Personal Care space.</li>
<li>Sustainable improvements in profitability appear to be the main reason for this dynamic.</li>
<li>In the coming years, however, P&amp;G would more likely trail sector returns, rather than outperforming them.</li>
</ul>


Over the past few years Procter &amp; Gamble has been outperforming its peers in the Home &amp; Personal Care space.
Sustainable improvements in profitability appear to be the main reason for this dynamic.
In the coming years, however, P&amp;G would more likely trail sector returns, rather than outperforming them.


Procter & Gamble - Set Your Expectations Right

<ul><li>Gross profitability is one of the most important financial metrics of the business and is indicative of its portfolio brand strength.</li><li>Contrary to the popular belief that the company has limited pricing power, premiumization has been key for addressing the risk of rising costs.</li><li>At the moment Colgate appears to be trading at attractive levels relative to its business fundamentals.</li></ul>

Gross profitability is one of the most important financial metrics of the business and is indicative of its portfolio brand strength.Contrary to the popular belief that the company has limited pricing power, premiumization has been key for addressing the risk of rising costs.At the moment Colgate appears to be trading at attractive levels relative to its business fundamentals.

Colgate-Palmolive Could Once Again Outperform Its Peers

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<div><p><a href="https://www.smartkarma.com/entities/cheerwin" target="_blank" data-smartkarma-citation="entities:31314:1" rel="noopener">Cheerwin (6601 HK)</a> is a leading consumer household care company in China that develops and manufactures a variety of household care, personal care and pet care products. Cheerwin will commence trading on Wednesday, 10 March. Cheerwin priced its IPO at HK$9.20 and <a href="https://inews.hket.com/article/2896489/%E3%80%90%E6%96%B0%E8%82%A1IPO%E3%80%91%E6%9C%9D%E9%9B%B2%E9%9B%86%E5%9C%986601%E6%9A%97%E7%9B%A4%E8%B7%8C2%E6%88%90%E3%80%80%E4%B8%80%E6%89%8B%E8%9D%95%E7%B4%841000%E5%85%83?mtc=40001&amp;srkw=IPO%E6%9C%80%E5%BF%AB%E6%9C%80%E9%BD%8A" target="_blank" rel="noopener">opened around -18% lower</a> at HK$7.52 in the grey market. The poor grey market performance is perhaps unsurprisingly in light of the choppy market conditions. </p></div><div><p>In <a href="https://www.smartkarma.com/insights/cheerwin-group-ipo-initiation-the-itch-of-fate" target="_blank" data-smartkarma-citation="insights:48373" rel="noopener">Cheerwin Group IPO Initiation: The Itch of Fate</a>, we opined that Cheerwin has the right ingredients to offer investors a play on another subsegment of China’s household care industry. We concluded that Cheerwin’s fundamentals are attractive. In <a href="https://www.smartkarma.com/insights/cheerwin-group-ipo-valuation-insights" target="_blank" data-smartkarma-citation="insights:48633" rel="noopener">Cheerwin Group IPO: Valuation Insights</a>, we noted that the IPO price range is resonable.</p></div><div><div><div class="content-highlight"><p>In many ways, the timing of Cheerwin's listing is unfortunate as <a href="https://www.smartkarma.com/entities/blue-moon-group-holdings" target="_blank" data-smartkarma-citation="entities:29179:1" rel="noopener">Blue Moon Group Holdings (6993 HK)</a>'s shares have derated -18% since Cheerwin launched its bookbuild. Updating for the final IPO net raise, our base-case DCF derived price target of HK$10.15 per share. Our DCF sensitivity analysis shows that the IPO price remains reasonable and the grey market factors in conservative market share and margin forecasts. For investors with a longer-term horizon, we think that the grey market price represents good value. </p></div></div></div>

Cheerwin (6601 HK) is a leading consumer household care company in China that develops and manufactures a variety of household care, personal care and pet care products. Cheerwin will commence trading on Wednesday, 10 March. Cheerwin priced its IPO at HK$9.20 and opened around -18% lower at HK$7.52 in the grey market. The poor grey market performance is perhaps unsurprisingly in light of the choppy market conditions. In Cheerwin Group IPO Initiation: The Itch of Fate, we opined that Cheerwin has the right ingredients to offer investors a play on another subsegment of China’s household care industry. We concluded that Cheerwin’s fundamentals are attractive. In Cheerwin Group IPO: Valuation Insights, we noted that the IPO price range is resonable.In many ways, the timing of Cheerwin's listing is unfortunate as Blue Moon Group Holdings (6993 HK)'s shares have derated -18% since Cheerwin launched its bookbuild. Updating for the final IPO net raise, our base-case DCF derived price target of HK$10.15 per share. Our DCF sensitivity analysis shows that the IPO price remains reasonable and the grey market factors in conservative market share and margin forecasts. For investors with a longer-term horizon, we think that the grey market price represents good value. 

<div><p><a href="https://www.smartkarma.com/entities/cheerwin" target="_blank" data-smartkarma-citation="entities:31314:1" rel="noopener">Cheerwin (6601 HK)</a> is a leading consumer household care company in China that develops and manufactures a variety of household care, personal care and pet care products. At the proposed IPO price range of HK$7.80-9.20 per share, Cheerwin will have a market cap of HK$10,400.0-12,266.7 million ($1.3-1.6 billion). At the mid-point of the IPO price range, the net proceeds are HK$2,663.9 million ($343 million). </p></div><div><div class="content-highlight"><p>In <a href="https://www.smartkarma.com/insights/cheerwin-group-ipo-initiation-the-itch-of-fate" target="_blank" data-smartkarma-citation="insights:48373" rel="noopener">Cheerwin Group IPO Initiation: The Itch of Fate</a>, we opined that Cheerwin has the right ingredients to offer investors a play on another subsegment of China’s household care industry. We concluded that Cheerwin’s fundamentals are attractive. Despite the lack of cornerstone support, we would participate in the IPO due to a reasonable IPO price range. Our base-case DCF valuation is HK$10.04 per share. </p></div></div>

Cheerwin (6601 HK) is a leading consumer household care company in China that develops and manufactures a variety of household care, personal care and pet care products. At the proposed IPO price range of HK$7.80-9.20 per share, Cheerwin will have a market cap of HK$10,400.0-12,266.7 million ($1.3-1.6 billion). At the mid-point of the IPO price range, the net proceeds are HK$2,663.9 million ($343 million). In Cheerwin Group IPO Initiation: The Itch of Fate, we opined that Cheerwin has the right ingredients to offer investors a play on another subsegment of China’s household care industry. We concluded that Cheerwin’s fundamentals are attractive. Despite the lack of cornerstone support, we would participate in the IPO due to a reasonable IPO price range. Our base-case DCF valuation is HK$10.04 per share. 

United States

Colgate-Palmolive Company is a consumer products company that markets its products throughout the world.  The Company's products include toothpaste, toothbrushes, shampoos, deodorants, bar and liquid soaps, dishwashing liquid, and laundry products, as well as pet nutrition products for cats and dogs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Colgate Palmolive Co (CL US)

Colgate-Palmolive Company - Investment Thesis

Colgate-Palmolive delivered a decent result, surpassing revenue expectations of Wall Street as a result of continued business momentum. The...

Baptista Research

Procter & Gamble - Set Your Expectations Right

Over the past few years Procter & Gamble has been outperforming its peers in the Home & Personal Care space. Sustainable improvements in...

Vladimir Dimitrov, CFA

Colgate-Palmolive Could Once Again Outperform Its Peers

Gross profitability is one of the most important financial metrics of the business and is indicative of its portfolio brand strength. Contrary to...

Vladimir Dimitrov, CFA

Cheerwin Group IPO: Trading Debut

Cheerwin priced its IPO at HK$9.20 and opened around -18% lower at HK$7.52 in the grey market. For investors with a longer-term horizon, we think...

Arun George

Cheerwin Group IPO: Valuation Insights

Cheerwin has launched its HK IPO to raise net proceeds of $343m at the mid-point of the HK$7.80-9.20 price range. The price range is attractive...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)